Real-World data shows promise for lenvatinib in advanced liver cancer
NCT ID NCT07298538
First seen Jan 07, 2026
Summary
This study looked back at medical records from 800 patients with unresectable liver cancer who were treated with lenvatinib-based therapy at six hospitals. Researchers analyzed how long patients survived, how well the cancer responded, and any side effects. The goal is to better understand real-world outcomes for this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, 300060, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
lenvatinib
What this could lead to
If successful, this study could confirm lenvatinib-based therapy as a standard option for extending survival in patients with unresectable liver cancer.
What could go wrong
This is a retrospective review, not a controlled trial, so results may be influenced by patient selection and other factors. It cannot prove cause and effect.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.